370 related articles for article (PubMed ID: 32321775)
21. Identification of Potent CD19 scFv for CAR T Cells through scFv Screening with NK/T-Cell Line.
Kang CH; Kim Y; Lee HK; Lee SM; Jeong HG; Choi SU; Park CH
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271901
[TBL] [Abstract][Full Text] [Related]
22. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies.
Poirot L; Philip B; Schiffer-Mannioui C; Le Clerre D; Chion-Sotinel I; Derniame S; Potrel P; Bas C; Lemaire L; Galetto R; Lebuhotel C; Eyquem J; Cheung GW; Duclert A; Gouble A; Arnould S; Peggs K; Pule M; Scharenberg AM; Smith J
Cancer Res; 2015 Sep; 75(18):3853-64. PubMed ID: 26183927
[TBL] [Abstract][Full Text] [Related]
23. Chimeric antigen receptor (CAR) T cells targeting a pathogenic MHC class II:peptide complex modulate the progression of autoimmune diabetes.
Zhang L; Sosinowski T; Cox AR; Cepeda JR; Sekhar NS; Hartig SM; Miao D; Yu L; Pietropaolo M; Davidson HW
J Autoimmun; 2019 Jan; 96():50-58. PubMed ID: 30122420
[TBL] [Abstract][Full Text] [Related]
24. CRISPR/Cas systems to overcome challenges in developing the next generation of T cells for cancer therapy.
Huang D; Miller M; Ashok B; Jain S; Peppas NA
Adv Drug Deliv Rev; 2020; 158():17-35. PubMed ID: 32707148
[TBL] [Abstract][Full Text] [Related]
25. Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies.
Collinson-Pautz MR; Chang WC; Lu A; Khalil M; Crisostomo JW; Lin PY; Mahendravada A; Shinners NP; Brandt ME; Zhang M; Duong M; Bayle JH; Slawin KM; Spencer DM; Foster AE
Leukemia; 2019 Sep; 33(9):2195-2207. PubMed ID: 30816327
[TBL] [Abstract][Full Text] [Related]
26. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
27. Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy.
Mo F; Duan S; Jiang X; Yang X; Hou X; Shi W; Carlos CJJ; Liu A; Yin S; Wang W; Yao H; Yu Z; Tang Z; Xie S; Ding Z; Zhao X; Hammock BD; Lu X
Signal Transduct Target Ther; 2021 Feb; 6(1):80. PubMed ID: 33627635
[TBL] [Abstract][Full Text] [Related]
28. Engineering Tolerance toward Allogeneic CAR-T Cells by Regulation of MHC Surface Expression with Human Herpes Virus-8 Proteins.
Wang X; Cabrera FG; Sharp KL; Spencer DM; Foster AE; Bayle JH
Mol Ther; 2021 Feb; 29(2):718-733. PubMed ID: 33554868
[TBL] [Abstract][Full Text] [Related]
29. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer.
Marcus A; Eshhar Z
Expert Opin Biol Ther; 2014 Jul; 14(7):947-54. PubMed ID: 24661086
[TBL] [Abstract][Full Text] [Related]
31. High-Specificity CRISPR-Mediated Genome Engineering in Anti-BCMA Allogeneic CAR T Cells Suppresses Allograft Rejection in Preclinical Models.
Degagné É; Donohoue PD; Roy S; Scherer J; Fowler TW; Davis RT; Reyes GA; Kwong G; Stanaway M; Larroca Vicena V; Mutha D; Guo R; Edwards L; Schilling B; Shaw M; Smith SC; Kohrs B; Kufeldt HJ; Churchward G; Ruan F; Nyer DB; McSweeney K; Irby MJ; Fuller CK; Banh L; Toh MS; Thompson M; Owen ALG; An Z; Gradia S; Skoble J; Bryan M; Garner E; Kanner SB
Cancer Immunol Res; 2024 Apr; 12(4):462-477. PubMed ID: 38345397
[TBL] [Abstract][Full Text] [Related]
32. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
33. Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.
Muller YD; Ferreira LMR; Ronin E; Ho P; Nguyen V; Faleo G; Zhou Y; Lee K; Leung KK; Skartsis N; Kaul AM; Mulder A; Claas FHJ; Wells JA; Bluestone JA; Tang Q
Front Immunol; 2021; 12():686439. PubMed ID: 34616392
[TBL] [Abstract][Full Text] [Related]
34. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia.
Rozenbaum M; Meir A; Aharony Y; Itzhaki O; Schachter J; Bank I; Jacoby E; Besser MJ
Front Immunol; 2020; 11():1347. PubMed ID: 32714329
[TBL] [Abstract][Full Text] [Related]
35. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Plückthun A; Riddell SR
Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
[TBL] [Abstract][Full Text] [Related]
36. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced
Xu X; Huang W; Heczey A; Liu D; Guo L; Wood M; Jin J; Courtney AN; Liu B; Di Pierro EJ; Hicks J; Barragan GA; Ngai H; Chen Y; Savoldo B; Dotti G; Metelitsa LS
Clin Cancer Res; 2019 Dec; 25(23):7126-7138. PubMed ID: 31484667
[TBL] [Abstract][Full Text] [Related]
37. Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.
Urak R; Walter M; Lim L; Wong CW; Budde LE; Thomas S; Forman SJ; Wang X
J Immunother Cancer; 2017; 5():26. PubMed ID: 28331616
[TBL] [Abstract][Full Text] [Related]
38. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
Front Immunol; 2019; 10():3123. PubMed ID: 32117200
[TBL] [Abstract][Full Text] [Related]
39. [Development of allogeneic CAR T-cells].
Alcazer V; Depil S
Bull Cancer; 2021 Oct; 108(10S):S73-S80. PubMed ID: 34920810
[TBL] [Abstract][Full Text] [Related]
40. Simultaneous editing of TCR, HLA-I/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection.
Li W; Zhu X; Xu Y; Chen J; Zhang H; Yang Z; Qi Y; Hong J; Li Y; Wang G; Shen J; Qian C
Front Immunol; 2022; 13():1052717. PubMed ID: 36532006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]